FDA Deems Angiomax sNDA "Not Approvable"
This article was originally published in The Pink Sheet Daily
Executive Summary
Bivalirudin supplemental application for patients undergoing percutaneous coronary intervention contained deficiencies in both the study methods and the analysis, FDA finds. Drug sponsor The Medicines Company plans to request a meeting with the agency.